Trial Search Results

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with hepatocellular carcinoma who have failed prior systemic treatment (chemotherapy). Hepatocellular carcinomas have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the hepatocellular carcinoma cells will starve and die.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Polaris Group

Stanford Investigator(s):


  • Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
  • Drug: Placebo
  • Other: Best Supportive Care


Phase 3


Inclusion Criteria:

   - Prior diagnosis of HCC confirmed histologically.

   - Prior treatment with at least 1 systemic agent, with documented progressive disease
   after systemic agent(s), or adverse event(s)associated with prior systemic agent(s)
   that resulted in discontinuance of that agent(s).

   - Cirrhotic status of Child-Pugh grade B7.

   - Expected survival of at least 3 months.

   - Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

   - Candidate for potential curative therapies (i.e., resection or transplantation) or
   loco-regional approaches (i.e., ablation, embolization).

   - Significant cardiac disease.

   - Serious infection requiring treatment with systemically administered antibiotics.

   - Pregnancy or lactation.

   - Expected non-compliance.

   - Uncontrolled intercurrent illness, or psychiatric illness or social situations that
   would limit compliance with study requirements.

   - Subjects who have had any anticancer treatment within 2 weeks prior to entering the

   - Subjects who have not fully recovered from toxicities associated with previous HCC
   loco-regional or systemic therapies.

   - Subjects with history of another primary cancer, with the exception of: a) curatively
   resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ;
   or c) other primary solid tumor with no known active disease present in the opinion of
   the investigator will not affect patient outcome in the setting of current HCC

   - Allergy to pegylated products.

   - Bleeding esophageal or gastric varices within the prior three months, except if banded
   or treated.

   - Subjects known to be HIV positive.

   - Uncontrolled ascites (defined as not easily controlled with diuretic treatment).

   - Having received any blood transfusion, blood component preparation, erythropoietin,
   albumin preparation, or granulocyte colony stimulating factors (G-CSF) within 7 days
   prior to screening laboratories or after screening laboratories have been obtained
   until first dose of study drug or placebo.

   - Use of traditional medicines approved by local authorities, including but not limited
   to Chinese herbs within 14 days of first dose of study drug or placebo.

   - ECOG performance status > 2.

   - Prior allograft,including liver transplant.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting